Obesity and Erectile Dysfunction: From Bench to Clinical Implication
Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both condi-tions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society for Sexual Medicine and Andrology
2019-05-01
|
Series: | The World Journal of Men's Health |
Subjects: |
id |
doaj-9f2b3dd10bb34b5f8e39d6707363888b |
---|---|
record_format |
Article |
spelling |
doaj-9f2b3dd10bb34b5f8e39d6707363888b2020-11-24T22:07:27ZengKorean Society for Sexual Medicine and AndrologyThe World Journal of Men's Health2287-42082287-46902019-05-0137213814710.5534/wjmh.180026Obesity and Erectile Dysfunction: From Bench to Clinical ImplicationKi Hak Moon0So Young Park1Yong Woon Kim2Departments of Urology and Physiology, Yeungnam University College of Medicine, Daegu, KoreaDepartments of Urology and Physiology, Yeungnam University College of Medicine, Daegu, KoreaDepartments of Urology and Physiology, Yeungnam University College of Medicine, Daegu, KoreaObesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both condi-tions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and leptin resistance. Moreover, the severity of ED is correlated with comorbid medical conditions, including obesity. Therefore, amelioration of these comorbidities may increase the efficacy of ED treatment with phosphodiesterase 5 inhibitors, the first-line medication for patients with ED. Although metformin was originally developed as an insulin sensitizer six decades ago, it has also been shown to improve leptin resistance. In addition, metformin has been reported to reduce oxidative stress, inflammatory response, and body weight, as well as improve ED, in animal and human studies. Moreover, administration of a combination of metformin and phosphodiesterase 5 inhibitors improves erectile function in patients with ED who have a poor response to sildenafil and are insulin resistant. Thus, con-comitant treatment of metabolic derangements associated with obesity in patients with ED who are obese would improve the efficacy and reduce the refractory response to penile vasodilators. In this review, we discuss the connecting factors between obesity and ED and the possible combined treatment modalities.Erectile dysfunctionMetforminObesityPhosphodiesterase 5 inhibitors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ki Hak Moon So Young Park Yong Woon Kim |
spellingShingle |
Ki Hak Moon So Young Park Yong Woon Kim Obesity and Erectile Dysfunction: From Bench to Clinical Implication The World Journal of Men's Health Erectile dysfunction Metformin Obesity Phosphodiesterase 5 inhibitors |
author_facet |
Ki Hak Moon So Young Park Yong Woon Kim |
author_sort |
Ki Hak Moon |
title |
Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_short |
Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_full |
Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_fullStr |
Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_full_unstemmed |
Obesity and Erectile Dysfunction: From Bench to Clinical Implication |
title_sort |
obesity and erectile dysfunction: from bench to clinical implication |
publisher |
Korean Society for Sexual Medicine and Andrology |
series |
The World Journal of Men's Health |
issn |
2287-4208 2287-4690 |
publishDate |
2019-05-01 |
description |
Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both condi-tions may share an internal pathologic environment, also known as common soil. Their main pathophysiologic processes are oxidative stress, inflammation, and resultant insulin and leptin resistance. Moreover, the severity of ED is correlated with comorbid medical conditions, including obesity. Therefore, amelioration of these comorbidities may increase the efficacy of ED treatment with phosphodiesterase 5 inhibitors, the first-line medication for patients with ED. Although metformin was originally developed as an insulin sensitizer six decades ago, it has also been shown to improve leptin resistance. In addition, metformin has been reported to reduce oxidative stress, inflammatory response, and body weight, as well as improve ED, in animal and human studies. Moreover, administration of a combination of metformin and phosphodiesterase 5 inhibitors improves erectile function in patients with ED who have a poor response to sildenafil and are insulin resistant. Thus, con-comitant treatment of metabolic derangements associated with obesity in patients with ED who are obese would improve the efficacy and reduce the refractory response to penile vasodilators. In this review, we discuss the connecting factors between obesity and ED and the possible combined treatment modalities. |
topic |
Erectile dysfunction Metformin Obesity Phosphodiesterase 5 inhibitors |
work_keys_str_mv |
AT kihakmoon obesityanderectiledysfunctionfrombenchtoclinicalimplication AT soyoungpark obesityanderectiledysfunctionfrombenchtoclinicalimplication AT yongwoonkim obesityanderectiledysfunctionfrombenchtoclinicalimplication |
_version_ |
1725820389969362944 |